| Alex Thurman |
Alex Thurman is currently the Chief Financial Officer & Senior Vice President at Glaukos Corp. and the Vice President-Finance at Allergan Ltd. (Ireland). He has an undergraduate and graduate degree from Brigham Young University. |
| Gabriella Szekely |
Gabriella Szekely is currently working as the VP-Combination Pharmaceutical Products Research at Glaukos Corp. She previously worked as the Vice President-Translational Sciences at Allergan, Inc. from 2008 to 2015. Dr. Szekely holds a doctorate degree from Michigan State University (conferred in 1997) and the University of Debrecen (conferred in 1989). |
| Joseph E. Gilliam |
Joseph E. Gilliam's current jobs include being a Director at Avedro, Inc. since 2019, a Director at Caris Life Sciences, LLC since 2021, and the President & Chief Operating Officer at Glaukos Corp. since 2017. Previously, he worked as a Managing Director-Healthcare Investment Banking at JPMorgan Chase & Co. from 2001 to 2017. He completed his undergraduate degree at Kelley School of Business in 1998. |
| Jay L. Katz |
Jay L. Katz is currently the Director of Glaucoma Service at Wills Eye Health System & Wills Eye Institute since 1985 and the Chief Medical Officer at Glaukos Corp. since 2017. He previously worked as the Treasurer & Director at American Glaucoma Society, Professor-Ophthalmology at Sidney Kimmel Medical College, and President-Philadelphia Metro chapter at American College of Surgeons. He completed his undergraduate degree at Case Western Reserve University and received his doctorate from Yale University in 1979. |
| Tomas Navratil |
Tomas Navratil is currently the Chief Development Officer at Glaukos Corp. He also holds a position on the Member-Supervisory Board at Severomoravske Vodovody a Kanalizace Ostrava as. Previously, he worked as the Director-Medical & Scientific Affairs at Inspire Pharmaceuticals, Inc., the Executive Director-Clinical Research at Parion Sciences, Inc., the General Manager at Nicox Ophthalmics, Inc., the Executive VP, Global Head-Research & Development at Nicox SA, and the Senior Vice President-Development at Envisia Therapeutics, Inc. Dr. Navratil obtained his undergraduate and doctorate degrees from The University of North Carolina at Charlotte. |
| Chris M. Calcaterra |
Chris M. Calcaterra is currently the EVP-Global Commercial Operations at Glaukos Corp. Prior to his current position, he held the role of Director at WaveTec Vision Systems, Inc. and Vice President-Sales & Marketing at Allergan, Inc. He also served as Senior Vice President at Advanced Medical Optics, Inc. from 2007 to 2008 and held the position of Senior Vice President at Cataract, Inc. Mr. Calcaterra obtained an MBA from Xavier University in 1997 and completed his undergraduate degree at Miami University in 1982. |
| Thomas William Burns |
Mr. Thomas W. Burns is an Independent Director at Pulmonx Corp. and a Chairman & Chief Executive Officer at Glaukos Corp. He is on the Board of Directors at Pulmonx Corp. Mr. Burns was previously employed as an Independent Director by Avedro, Inc., a Chairman by DOSE Medical Corp., a VP-Global Strategy & GM-Refractive Surgery by Bausch & Lomb, Inc., a Senior Vice President & General Manager by Chiron Vision Corp., a President, Chief Operating Officer & Director by Oldtech, Inc., and an Entrepreneur-in-Residence by Versant Venture Management LLC. He received his undergraduate degree from Yale University. |
| Leana S. Wen |
Leana S. Wen is currently an Independent Director at Glaukos Corp., a Director at Baltimore Community Foundation, a Director at Bipartisan Policy Center, a Director at UroGen Pharma Ltd., and a Professor at Milken Institute School of Public Health. Previously, she served as the Chairman of Behavioral Health System Baltimore, the Director of Patient Centered Care Research at George Washington University from 2013 to 2015, the Commissioner of the Baltimore Health Department from 2015 to 2018, and the President of Planned Parenthood Federation of America, Inc. from 2018 to 2019. Dr. Wen holds a graduate degree from the University of Oxford, an undergraduate degree from California State University-Los Angeles, and a doctorate degree from Washington University School of Medicine. |
| David F. Hoffmeister |
David F. Hoffmeister is currently an Independent Director at ICU Medical, Inc. and Celanese Corp. He is also a Director at Kaiser Permanente Washington Health Research Institute, Kaiser Permanente, Inc., Kaiser Foundation Hospitals, Kaiser Permanente of Northern California, Kaiser Permanente of Mid Atlantic States, and Kaiser Foundation Health Plan, Inc. Additionally, he serves as an Independent Director at StepStone Group, Inc. and as the President of BioTrove, Inc. In the past, Mr. Hoffmeister held positions as a Director at Protometrix, Inc., Principal at GTE Corp., and President at W. R. Grace & Co.-Conn. He was also the Chief Financial Officer & Senior Vice President at Invitrogen Corp. from 2004 to 2008, and a Senior Partner at McKinsey & Co., Inc. from 1984 to 2004. From 2008 to 2014, he served as the Chief Financial Officer & Senior Vice President at Life Technologies Corp.Mr. Hoffmeister obtained an MBA from The University of Chicago and an undergraduate degree from the University of Minnesota. |
| Denice M. Torres |
Denice M. Torres is the founder of The Mentoring Place (founded in 2017) and Ignited LLC (founded in 2017), where she holds the title of Chief Executive Officer. Ms. Torres's current job(s) include being an Independent Director at Glaukos Corp. (since 2021), a Director at Wylei, Inc. (since 2018), a Director at National Resilience, Inc. (since 2020), an Independent Director at 2seventy Bio, Inc. (since 2021), and a Member of the State Bar of Michigan. Ms. Torres's former job(s) include being the Chairman of Surface Oncology, Inc. (from 2021 to 2023), an Executive Director-Global Neuroscience at Eli Lilly & Co. (from 1990 to 2004), an Independent Director at bluebird bio, Inc. (from 2020 to 2021), a Director at OWHealth, Inc., a Director at Thirty Madison, Inc., an Independent Director at Karuna Therapeutics, Inc. (from 2020 to 2024), the Chief Strategy & Transformation Officer at Johnson & Johnson (from 2015 to 2017), and the President of Janssen Pharmaceuticals, Inc. (from 2009 to 2011). She also held the title of President at NeuroScience, Inc. (from 2009 to 2011). Ms. Torres's education history includes an undergraduate degree from Ball State University (Indiana), an MBA from the University of Michigan (conferred in 1990), and a graduate degree from Indiana University Maurer School of Law. |
| Aimee S. Weisner |
Aimee S. Weisner is currently the Director at STAAR Surgical Co., Independent Director at LENSAR, Inc., Independent Director at Glaukos Corp., Director at NeuroSigma, Inc., and Director at American Heart Association of Orange County. Previously, she served as the Independent Director at Oyster Point Pharma, Inc. from 2019 to 2023. She also held positions as Director at Avellino Labs USA, Inc., Corporate Counsel & Assistant Secretary at Allergan, Inc. from 1998 to 2002, Vice President & General Counsel at Edwards Lifesciences Corp. from 2011 to 2019, Secretary, EVP-Administration & General Counsel at Advanced Medical Optics, Inc. in 2002, and Associate at O'Melveny & Myers LLP from 1994 to 1998. Ms. Weisner obtained an undergraduate degree from California State University-Fullerton and a graduate degree from Loyola Law School in 1994. |
| Marc A. Stapley |
Marc A. Stapley is currently the Chief Executive Officer & Director at Veracyte, Inc. and the Executive Chairman at Helix OpCo LLC. He is also an Independent Director at Glaukos Corp. Additionally, he holds positions as a Director at Premier Food Concepts LLC, Helix Holdings I, LLC, PCI Media, Inc., and is a Member of the Institute of Chartered Accountants in England & Wales. In his former roles, Mr. Stapley served as the Finance Director & Controller at Cadence Design Systems, Inc. from 1996 to 2001. He was also the Senior Vice President-Finance at Pfizer Inc. from 2009 to 2012 and the Chief Financial Officer at Nokia of America Corp. in 2009. From 2012 to 2019, he held the position of Executive VP-Strategy & Corporate Development at Illumina, Inc. Prior to that, he worked as an Auditor at Coopers & Lybrand LLP from 1991 to 1995. Mr. Stapley completed his undergraduate degree at The University of Reading in 1991. |
| Mark J. Foley |
Mark J. Foley was the founder of Ventrica, Inc. (founded in 1998) and held the title of President & Chief Executive Officer. Currently, Mr. Foley is the President, Chief Executive Officer & Director at Revance Therapeutics, Inc. (since 2017), Chairman at uLab Systems, Inc. (since 2015), and Lead Independent Director at Glaukos Corp. (since 2014). Mr. Foley's former positions include Chairman, President & Chief Executive Officer at ZELTIQ Aesthetics, Inc. (2012-2017), Executive Chairman at Onpharma, Inc. (2009-2014), Chairman at Arrinex, Inc. (2018-2019), and various director roles at BaroSense, Inc., Sonitus Medical, Inc., Voyage Medical, Inc., and Therative, Inc. Mr. Foley also served as an Independent Director at SI-BONE, Inc. (2019-2021) and as a Managing Director at RWI Ventures Management Company LLC (2004-2018). Additionally, Mr. Foley was a Director at Hint, Inc. (California) from 2017 to 2020. Mr. Foley obtained his undergraduate degree from the University of Notre Dame in 1987. |
| Gilbert H. Kliman |
Gil joined InterWest in 1996. As Managing Partner of the firm and the leader of InterWest’s Healthcare investment team.
Gil currently serves as an independent board member of Glaukos (NYSE: GKOS), a pioneering ophthalmic technology company focused on the development and commercialization of breakthrough devices and drugs to transform the treatment of eye diseases, STAAR Surgical (NASDAQ: STAA), a leading ophthalmology company commercializing the EVO implantable contact lens for nearsightedness, and Orbis International, a global not-for-profit organization focused on preventing blindness. He is also a co-founder and program director of Eyecelerator, a first-of-kind ophthalmology innovation conference supported by a joint venture of the American Academy of Ophthalmology and the American Society of Cataract and Refractive Surgery. Previously, he helped to launch the Ophthalmology Innovation Summit (OIS), an ophthalmology business conference where he was an advisor and founding co-chairman from 2009 to 2019.
He is a former board member and lead investor in Doximity (NYSE: DOCS), Avedro (NASDAQ: AVDR, acquired by Glaukos), Epocrates (NASDAQ: EPOC, acquired by athenahealth), LenSx Lasers (acquired by Alcon), IntraLase (NASDAQ: ILSE, acquired by AMO), Neuronetics (NASDAQ: STIM), Restoration Robotics (NASDAQ: VERO, acquired by Venus Concept), and GoCheck.
A former practicing eye surgeon, Gil completed an ophthalmology residency at Wills Eye Hospital and a retina fellowship at Massachusetts Eye and Ear Infirmary as a Heed Foundation fellow. He has a BA from Harvard University, an MD from the University of Pennsylvania and an MBA from Stanford University. |
